There are 2934 resources available
Innovative Medicines Initiative: Calling for research on immunotherapies?
Presenter: Kjetil Tasken
Session: Immunotherapies: A revolution in cancer treatment, but are they accessible for all patients?
Resources:
Slides
Webcast
Patient perspective
Presenter: Bettina Ryll
Session: Immunotherapies: A revolution in cancer treatment, but are they accessible for all patients?
Resources:
Slides
Webcast
Proffered Paper 2 – Gynaecological cancers - Invited Discussant LBA62 and 994O
Presenter: Nicoletta Colombo
Session: Proffered Paper 2 – Gynaecological cancers
Resources:
Slides
Webcast
2738 - A Randomized Phase II/III Study to Assess the Efficacy of Trametinib in Patients with Recurrent or Progressive Low-Grade Serous Ovarian or Peritoneal Cancer
Presenter: David Gershenson
Session: Proffered Paper 2 – Gynaecological cancers
Resources:
Abstract
Slides
Webcast
5630 - Efficacy and safety of nivolumab (Nivo) + ipilimumab (Ipi) in patients (pts) with recurrent/metastatic (R/M) cervical cancer: Results from CheckMate 358
Presenter: Robert Naumann
Session: Proffered Paper 2 – Gynaecological cancers
Resources:
Abstract
Slides
Webcast
Personalised oncogenomics: Is a precision approach necessary for every cancer or is there a therapy-driven bottleneck?
Presenter: David Huntsman
Session: Molecular tumour board: Where do we stand? What’s next?
Resources:
Slides
Webcast
Tissue and liquid biopsies with MTB for phase 1 trial selection: Experience in the TARGET trial
Presenter: Matthew Krebs
Session: Molecular tumour board: Where do we stand? What’s next?
Resources:
Slides
Webcast
Building of a comprehensive clinical and molecular genomics database for patients with treatment-refractory cancers enrolled in clinical trials
Presenter: Philippe Bedard
Session: Molecular tumour board: Where do we stand? What’s next?
Resources:
Slides
Webcast
Frailty: Concept, biology, assessment and corrective measures
Presenter: Siri Rostoft
Session: ESMO-SIOG Collaborative session: Immunotherapy in older patients: Challenges and opportunities
Resources:
Slides
Webcast
2111 - Phase III randomized study of neoadjuvant chemotherapy (CT) with docetaxel(D), oxaliplatin(O) and S-1(S) (DOS) followed by surgery and adjuvant S-1, vs surgery and adjuvant S-1, for resectable advanced gastric cancer (GC) (PRODIGY)
Presenter: Yoon-Koo Kang
Session: Proffered Paper 2 – Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Slides